Linking molecular therapeutics to molecular diagnostics: inhibition of the FRAP/RAFT/TOR component of the PI3K pathway preferentially blocks PTEN mutant cells in vitro and in vivo.

Proceedings of the National Academy of Sciences of the United States of America ·Vol. 98 ·No. 18 ·2001-08-28 ·Pages 10031-3

Mills GB, Lu Y, Kohn EC

Abstract

暂无摘要

MeSH Terms

Animals Ataxia Telangiectasia Mutated Proteins Cell Cycle Proteins/antagonists & inhibitors Drosophila Proteins Enzyme Inhibitors/therapeutic use Focal Adhesion Kinase 2 Humans Mice Mice, Knockout Mutation Neoplasms, Experimental/drug therapy,genetics,metabolism PTEN Phosphohydrolase Phosphoinositide-3 Kinase Inhibitors Phosphoric Monoester Hydrolases/genetics Protein Serine-Threonine Kinases Protein-Tyrosine Kinases/antagonists & inhibitors Receptor Protein-Tyrosine Kinases/antagonists & inhibitors Signal Transduction Sirolimus/analogs & derivatives,therapeutic use Tumor Suppressor Proteins

Chemicals

Cell Cycle Proteins Drosophila Proteins Enzyme Inhibitors Phosphoinositide-3 Kinase Inhibitors Tumor Suppressor Proteins temsirolimus Atr protein, mouse Protein-Tyrosine Kinases Receptor Protein-Tyrosine Kinases tor protein, Drosophila Focal Adhesion Kinase 2 ATR protein, human Ataxia Telangiectasia Mutated Proteins Protein Serine-Threonine Kinases Phosphoric Monoester Hydrolases PTEN Phosphohydrolase PTEN protein, human Sirolimus

Authors & Affiliations

3 authors, click to expand affiliations / ORCID

Mills G B

Department of Molecular Therapeutics, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA. [email protected]

Lu Y

Kohn E C

References (33)

33 references, click to expand

Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas.
Int J Cancer. 1995 Aug 22;64(4):280-5 PMID: 7657393
Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.
Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10314-9 PMID: 11504908
Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers.
Nat Genet. 1997 Apr;15(4):356-62 PMID: 9090379
TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta.
Cancer Res. 1997 Jun 1;57(11):2124-9 PMID: 9187108
Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression.
Proc Natl Acad Sci U S A. 1998 Apr 28;95(9):5246-50 PMID: 9560261
PIK3CA is implicated as an oncogene in ovarian cancer.
Nat Genet. 1999 Jan;21(1):99-102 PMID: 9916799
PTEN is inversely correlated with the cell survival factor Akt/PKB and is inactivated via multiple mechanismsin haematological malignancies.
Hum Mol Genet. 1999 Feb;8(2):185-93 PMID: 9931326
PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer.
Science. 1997 Mar 28;275(5308):1943-7 PMID: 9072974
An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice.
Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10320-5 PMID: 11504907
The role of genetic abnormalities of PTEN and the phosphatidylinositol 3-kinase pathway in breast and ovarian tumorigenesis, prognosis, and therapy.
Semin Oncol. 2001 Oct;28(5 Suppl 16):125-41 PMID: 11706404
Activity of rapamycin (AY-22,989) against transplanted tumors.
J Antibiot (Tokyo). 1984 Oct;37(10):1231-7 PMID: 6501094
Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro.
Cancer Res. 1995 May 1;55(9):1982-8 PMID: 7728769
In vitro and in vivo antitumor activity of the phosphatidylinositol-3-kinase inhibitor, wortmannin.
Anticancer Res. 1995 Jul-Aug;15(4):1135-9 PMID: 7653991
Up-regulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines.
J Biol Chem. 1999 Jul 30;274(31):21528-32 PMID: 10419456
p70 S6 kinase-mediated protein synthesis is a critical step for vascular endothelial cell proliferation.
J Biol Chem. 1999 Sep 17;274(38):26776-82 PMID: 10480882
The PTEN/MMAC1/TEP tumor suppressor gene decreases cell growth and induces apoptosis and anoikis in breast cancer cells.
Oncogene. 1999 Nov 25;18(50):7034-45 PMID: 10597304
PI-3 kinase in signal transduction, cell transformation, and as a target for chemoprevention of cancer.
Anticancer Res. 1999 Sep-Oct;19(5A):3743-7 PMID: 10625951
In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002).
Clin Cancer Res. 2000 Mar;6(3):880-6 PMID: 10741711
Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics.
Cancer Res. 2000 Mar 15;60(6):1541-5 PMID: 10749120
Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer.
Oncogene. 2000 May 4;19(19):2324-30 PMID: 10822383
Phosphorylation of the PTEN tail regulates protein stability and function.
Mol Cell Biol. 2000 Jul;20(14):5010-8 PMID: 10866658
Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis.
J Natl Cancer Inst. 2000 Aug 2;92(15):1252-9 PMID: 10922410
Integrin-linked kinase (ILK): a "hot" therapeutic target.
Biochem Pharmacol. 2000 Oct 15;60(8):1115-9 PMID: 11007949
Epigenetic PTEN silencing in malignant melanomas without PTEN mutation.
Am J Pathol. 2000 Oct;157(4):1123-8 PMID: 11021816
PTEN methylation is associated with advanced stage and microsatellite instability in endometrial carcinoma.
Int J Cancer. 2001 Jan 1;91(1):22-6 PMID: 11149415
A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt.
Proc Natl Acad Sci U S A. 2001 Jan 2;98(1):136-41 PMID: 11134523
The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus. Implications for PTEN stability to proteasome-mediated degradation.
J Biol Chem. 2001 Jan 12;276(2):993-8 PMID: 11035045
PTEN: life as a tumor suppressor.
Exp Cell Res. 2001 Mar 10;264(1):29-41 PMID: 11237521
Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy.
Cancer Res. 2001 Feb 15;61(4):1527-32 PMID: 11245461
Regulation of translation initiation by FRAP/mTOR.
Genes Dev. 2001 Apr 1;15(7):807-26 PMID: 11297505
p53/p21(CIP1) cooperate in enforcing rapamycin-induced G(1) arrest and determine the cellular response to rapamycin.
Cancer Res. 2001 Apr 15;61(8):3373-81 PMID: 11309295
Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas.
Am J Pathol. 2001 Jun;158(6):2097-106 PMID: 11395387
The rapamycin-sensitive signal transduction pathway as a target for cancer therapy.
Oncogene. 2000 Dec 27;19(56):6680-6 PMID: 11426655

Article Info

Journal

Proceedings of the National Academy of Sciences of the United States of America

Abbr.

Proc Natl Acad Sci U S A

ISSN

0027-8424

DOI

10.1073/pnas.191379498

[email protected]

Published

2001-08-28

Pages

10031-3

Language

English

Region

United States

NLM ID

7505876

PMCID

PMC56908

Subset

Corrections

CommentOn

PMID: 11504907

CommentOn

PMID: 11504908

External Links

PubMed source DOI: 10.1073/pnas.191379498 PMC Full Text View journal details

Analysis Services

Linking molecular therapeutics to molecular diagnostics: inhibition of the FRAP/RAFT/TOR component of the PI3K pathway preferentially blocks PTEN mutant cells in vitro and in vivo.

Contact

WeChat Official Account